1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]

Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]

  • May 2018
  • ID: 5438897
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Are novel therapies set to revolutionise NASH?

No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but this could all change in the next 3-5 years. Four late-stage pipeline programmes are advancing through development, and 16 mid-stage pipeline programmes are also making progress. Which ones will pass muster? And which ones do leading key opinion leaders (KOLs) believe will have the biggest impact on the future treatment paradigm for NASH? Will it be cenicriviroc (Allergan), selonsertib (Gilead), obeticholic acid (Intercept Pharmaceuticals), or elafibranor (Genfit)?

Learn how 12 of the world’s leading KOLs from Europe and the US see the NASH treatment landscape evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic Steatohepatitis (NASH).

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• Will Intercept’s obeticholic acid be the first-to-market? The US FDA has issued a boxed warning for Ocaliva in PBC patients regarding liver damage. Is this likely to affect its chances in NASH?
• How do KOLs rate the next-generation of FXR agonists? Enanta, Gilead and Novartis are developing agents in this space but which one stands out and can they challenge obeticholic acid?
• How clinically attractive is Genfit’s elafibranor? The REGENERATE trial is in progress but what advantages do KOL think elafibranor has over its competitors?
• How do KOLs view the progress of Allergan’s cenicriviroc? The Phase III AURORA study has been initiated based on the data from the CENTAUR Phase IIb study, but how do KOLs rate this data?
• How do KOLs rate the potential of Gilead’s STELLAR 3/4 studies for NASH? Do KOLs believe selonsertib monotherapy has a future or should the company focus on its parallel combination strategy?
• How do KOLs rate saroglitazar’s chances? Phase III studies are underway in India, but with saroglitazar only in Phase II trials in the US, is it too early for KOLs to have a view?
• Can Inventiva’s pan-PPAR agonist, lanifibranor, challenge Genfit’s elafibranor and Zydus’ saroglitazar? What potential do KOLs think PPARs have in NASH?
• How is the Phase II data for Conatus’ emricasan perceived by KOLs? What do they say about the designs of ENCORE-PH and ENCORE-NF Phase II studies for the agent?
• Will Galmed’s Aramchol find a place in NASH? What do experts think about the Phase II ARRIVE study data and will it affect its NASH development?
• Will Novo Nordisk’s GLP-1 agonist semaglutide find a place in NASH? The antidiabetic agent is useful for treating insulin resistance but will it show anti-fibrotic effects? KOLs provide their views.
• What do KOLs expect from FGFR inhibitors in NASH? MGL-3196 (Madrigal), BMS-986036 (BMS) and NGM282 (NGM Biopharma) are competing in this space but which candidate stands out?
• How do KOLs view other novel agents/MOAs such as volixibat (Shire) and Boehringer Ingelheim’s BI 1467335 and Can-Fite’s namodenoson? Will they have an impact in NASH?

Quotes

“Clearly, there’s a persistent unmet need for treatments and to refine the populations who need treatment. An even more urgent unmet need is to have better, non-invasive diagnostics and strategies for screening of patients who either have NASH, or are at risk for NASH.” US Key Opinion Leader

Sample of therapies covered

Late-stage Pipeline Therapies
• Obeticholic acid (Ocaliva; Intercept Pharmaceuticals)
• Elafibranor (Genfit Pharmaceuticals)
• Selonsertib (Gilead)
• Cenicriviroc (Allergan)

Mid-stage Pipeline Therapies
• Aramchol (Galmed Medical Research)
• BI 1467335 (Boehringer Ingelheim)
• BMS 986036 (Bristol-Myers Squibb)
• EDP 305 (Enanta Pharmaceuticals)
• Emricasan (Conatus/Idun/Novartis)
• GS 0976 (Gilead Sciences)
• GS 9674 (Gilead Sciences)
• IMM 124E (Immuron)
• Lanifibranor (Inventiva Pharma)
• MGL 3196 (Roche/Madrigal Pharmaceuticals)
• Namodenoson (Can-Fite BioPharma/Chong Kun Dang)
• NGM 282 (NGM Biopharmaceuticals)
• Saroglitazar (Zydus Cadila)
• Semaglutide (Novo Nordisk)
• Tropifexor (Novartis/Allergan)
• Volixibat (Shire/Sanofi)

KOLs interviewed

KOLs from North America
• Dr. Naim Alkhouri, MD; Staff Physician, Digestive Disease Institute and Cleveland Clinic’s Children Hospital, Cleveland, Ohio
• Prof Scott L. Friedman, MD; Dean for Therapeutic Discovery and Chief of Division of Liver Diseases, The Icahn School of Medicine, Mount Sinai Hospital, New York City
• Prof Joel E. Lavine, MD, PhD; Chief of the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Morgan Stanley Children’s Hospital and Columbia University Medical Center New York
• Prof Brent A. Neuschwander-Tetri, MD; FACP, FACG, AGAF; Director, Division of Gastroenterology and Hepatology and Professor of Internal Medicine, Saint Louis University School of Medicine in Missouri
• Prof Philip Rosenthal, MD; Director of Pediatric Hepatology, University of California, San Francisco (UCSF)
• Dr. Robert Wong, MD, MS; Assistant Clinical Professor at UCSF, Gastroenterology and Hepatology Faculty, California

KOLs from Europe
• Dr. Stefano Bellentani, MD, PhD; Gastroenterologist at Azienda USL di Modena, Italy
• Dr. Pinelopi Manousou, MD, PhD; Consultant Hepatologist at St Mary’s Hospital, Imperial College London, UK
• Dr. Stuart McPherson, MD, FRCP; Consultant Liver Specialist, Newcastle upon Tyne Hospital, UK
• Prof Phillip Newsome, MD; Professor of Experimental Hepatology, Director of the Centre for Liver Research and Clinical Director of the Birmingham University Stem Cell Centre, UK
• Dr. Valerio Nobili, MD; Consultant Hepatologist at Bambino Gesu Children’s Hospital, Rome, Italy
• Prof Vlad Ratziu, MD, PhD; Professor of Hepatology, Université Pierre et Marie Curie and the Hôpital Pitié-Salpêtrière Medical School, Paris, France

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Sutent (sunitinib malate) - Drug Insight and Market Forecast - 2030

Sutent (sunitinib malate) - Drug Insight and Market Forecast - 2030

  • $ 2750
  • February 2020

Overview“Sutent (sunitinib malate) - Drug Insight and Market Forecast – 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed ...

Male Hypogonadism - Pipeline Review, H1 2020

Male Hypogonadism - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Male Hypogonadism - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H1 2020, provides an overview of the Male Hypogonadism ...

Down Syndrome - Pipeline Review, H1 2020

Down Syndrome - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Down Syndrome - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Pipeline Review, H1 2020, provides an overview of the Down Syndrome (Genetic ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on